Promotion of the induction of cell pluripotency through metabolic remodeling by thyroid hormone triiodothyronine-activated PI3K/AKT signal pathway

Biomaterials

Volumn 33, Issue 22, 2012, Pages 5514-5523

  Chen, Mengfei ^a   Zhang, He ^b   Wu, Jie ^a   Xu, Liang ^a   Xu, Di ^a   Sun, Jingnan ^b   He, Yixin ^a   Zhou, Xin ^a   Wang, Zhaojing ^a   Wu, Lifang ^a   Xu, Shaokun ^a   Wang, Jinsong ^a   Jiang, Shu ^a   Zhou, Xiangjun ^a   Hoffman, Andrew R ^b   Hu, Xiang ^a   Hu, Jifan ^b   Li, Tao ^a  

^a Shenzhen Beike Cell Engineering Research Institute   (China)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Induced pluripotent stem cell; IPSC; Metabolic remodeling; PI3K AKT signal pathway; Reprogramming; T3

Indexed keywords

IPSC; METABOLIC REMODELING; PLURIPOTENT STEM CELLS; REPROGRAMMING; SIGNAL PATHWAYS; T3;

CELL CULTURE; CELL PROLIFERATION; GENES; HORMONES; STEM CELLS;

METABOLISM;

LIOTHYRONINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; ENZYME ACTIVATION; FIBROBLAST; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UMBILICAL CORD; UPREGULATION;

ADULT; CELL DIFFERENTIATION; CELLS, CULTURED; FIBROBLASTS; HEK293 CELLS; HUMANS; MALE; PHOSPHATIDYLINOSITOL 3-KINASES; PLURIPOTENT STEM CELLS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRIIODOTHYRONINE;

EID: 84861226152     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.04.001     Document Type: Article

References (51)

1. Takahashi K., Okita K., Nakagawa M., Yamanaka S. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc 2007, 2:3081-3089.
2. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
3. Wernig M., Zhao J.P., Pruszak J., Hedlund E., Fu D., Soldner F., et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A 2008, 105:5856-5861.
4. Hanna J., Wernig M., Markoulaki S., Sun C.W., Meissner A., Cassady J.P., et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007, 318:1920-1923.
5. Ye L., Chang J.C., Lin C., Sun X., Yu J., Kan Y.W. Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases. Proc Natl Acad Sci U S A 2009, 106:9826-9830.
6. Park I.H., Arora N., Huo H., Maherali N., Ahfeldt T., Shimamura A., et al. Disease-specific induced pluripotent stem cells. Cell 2008, 134:877-886.
7. Colman A., Dreesen O. Pluripotent stem cells and disease modeling. Cell Stem Cell 2009, 5:244-247.
8. Park I.H., Zhao R., West J.A., Yabuuchi A., Huo H., Ince T.A., et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008, 451:141-146.
9. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
10. Hussein S.M., Batada N.N., Vuoristo S., Ching R.W., Autio R., Narva E., et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011, 471:58-62.
11. Gore A., Li Z., Fung H.L., Young J.E., Agarwal S., Antosiewicz-Bourget J., et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011, 471:63-67.
12. Deng J., Shoemaker R., Xie B., Gore A., LeProust E.M., Antosiewicz-Bourget J., et al. Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nat Biotechnol 2009, 27:353-360.
13. Kim K., Doi A., Wen B., Ng K., Zhao R., Cahan P., et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010, 467:285-290.
14. Polo J.M., Liu S., Figueroa M.E., Kulalert W., Eminli S., Tan K.Y., et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol 2010, 28:848-855.
15. Lister R., Pelizzola M., Kida Y.S., Hawkins R.D., Nery J.R., Hon G., et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011, 471:68-73.
16. Pick M., Stelzer Y., Bar-Nur O., Mayshar Y., Eden A., Benvenisty N. Clone- and gene-specific aberrations of parental imprinting in human induced pluripotent stem cells. Stem Cells 2009, 27:2686-2690.
17. Stadtfeld M., Apostolou E., Akutsu H., Fukuda A., Follett P., Natesan S., et al. Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature 2010, 465:175-181.
18. Wernig M., Lengner C.J., Hanna J., Lodato M.A., Steine E., Foreman R., et al. A drug-inducible transgenic system for direct reprogramming of multiple somatic cell types. Nat Biotechnol 2008, 26:916-924.
19. Huangfu D., Osafune K., Maehr R., Guo W., Eijkelenboom A., Chen S., et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008, 26:1269-1275.
20. Kawamura T., Suzuki J., Wang Y.V., Menendez S., Morera L.B., Raya A., et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009, 460:1140-1144.
21. Marion R.M., Strati K., Li H., Murga M., Blanco R., Ortega S., et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009, 460:1149-1153.
22. Li H., Collado M., Villasante A., Strati K., Ortega S., Canamero M., et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009, 460:1136-1139.
23. Shi Y., Desponts C., Do J.T., Hahm H.S., Scholer H.R., Ding S. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell 2008, 3:568-574.
24. Esteban M.A., Wang T., Qin B., Yang J., Qin D., Cai J., et al. Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell 2009, 6:71-79.
25. Lin T., Ambasudhan R., Yuan X., Li W., Hilcove S., Abujarour R., et al. A chemical platform for improved induction of human iPSCs. Nat Methods 2009, 6:805-808.
26. Jaenisch R., Young R. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell 2008, 132:567-582.
27. Miura T., Mattson M.P., Rao M.S. Cellular lifespan and senescence signaling in embryonic stem cells. Aging Cell 2004, 3:333-343.
28. White J., Dalton S. Cell cycle control of embryonic stem cells. Stem Cell Rev 2005, 1:131-138.
29. Becker K.A., Ghule P.N., Therrien J.A., Lian J.B., Stein J.L., van Wijnen A.J., et al. Self-renewal of human embryonic stem cells is supported by a shortened G1 cell cycle phase. J Cell Physiol 2006, 209:883-893.
30. Paus R., Arck P., Tiede S. (Neuro-)endocrinology of epithelial hair follicle stem cells. Mol Cell Endocrinol 2008, 288:38-51.
31. Hu J.F., Oruganti H., Vu T.H., Hoffman A.R. The role of histone acetylation in the allelic expression of the imprinted human insulin-like growth factor II gene. Biochem Biophys Res Commun 1998, 251:403-408.
32. Hu J.F., Vu T.H., Hoffman A.R. Genomic deletion of an imprint maintenance element abolishes imprinting of both insulin-like growth factor II and H19. J Biol Chem 1997, 272:20715-20720.
33. Li T., Hu J.F., Qiu X., Ling J., Chen H., Wang S., et al. CTCF regulates allelic expression of Igf2 by orchestrating a promoter-polycomb repressive complex-2 intrachromosomal loop. Mol Cell Biol 2008, 28:6473-6482.
34. Hu J.F., Vu T.H., Hoffman A.R. Promoter-specific modulation of insulin-like growth factor II genomic imprinting by inhibitors of DNA methylation. J Biol Chem 1996, 271:18253-18262.
35. Chen H.L., Li T., Qiu X.W., Wu J., Ling J.Q., Sun Z.H., et al. Correction of aberrant imprinting of IGF2 in human tumors by nuclear transfer-induced epigenetic reprogramming. EMBO J 2006, 25:5329-5338.
36. Zhu X.Q., Pan X.H., Wang W., Chen Q., Pang R.Q., Cai X.M., et al. Transient in vitro epigenetic reprogramming of skin fibroblasts into multipotent cells. Biomaterials 2009, 31:2779-2787.
37. Zhang H., Niu B., Hu J.F., Wang H., Ling J., Qian G., et al. Interruption of intrachromosomal looping by CTCF decoy proteins abrogates genomic imprinting of human insulin-like growth factor II. J Cell Biol 2011, 193:475-487.
38. Schapira M., Raaka B.M., Das S., Fan L., Totrov M., Zhou Z., et al. Discovery of diverse thyroid hormone receptor antagonists by high-throughput docking. Proc Natl Acad Sci U S A 2003, 100:7354-7359.
39. Vlahos C.J., Matter W.F., Hui K.Y., Brown R.F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994, 269:5241-5248.
40. Chen T., Yuan D., Wei B., Jiang J., Kang J., Ling K., et al. E-cadherin-mediated cell-cell contact is critical for induced pluripotent stem cell generation. Stem Cells 2010, 28:1315-1325.
41. Li R., Liang J., Ni S., Zhou T., Qing X., Li H., et al. A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell 2010, 7:51-63.
42. Bhargava M., Lei J., Ingbar D.H. Nongenomic actions of L-thyroxine and 3,5,3'-triiodo-L-thyronine. Focus on " L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase" . Am J Physiol Cell Physiol 2009, 296:C977-C979.
43. Yoshida Y., Takahashi K., Okita K., Ichisaka T., Yamanaka S. Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell 2009, 5:237-241.
44. Kondoh H., Lleonart M.E., Nakashima Y., Yokode M., Tanaka M., Bernard D., et al. A high glycolytic flux supports the proliferative potential of murine embryonic stem cells. Antioxid Redox Signal 2007, 9:293-299.
45. Wang J., Alexander P., Wu L., Hammer R., Cleaver O., McKnight S.L. Dependence of mouse embryonic stem cells on threonine catabolism. Science 2009, 325:435-439.
46. Facucho-Oliveira J.M., St John J.C. The relationship between pluripotency and mitochondrial DNA proliferation during early embryo development and embryonic stem cell differentiation. Stem Cell Rev 2009, 5:140-158.
47. Folmes C.D., Nelson T.J., Martinez-Fernandez A., Arrell D.K., Lindor J.Z., Dzeja P.P., et al. Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. Cell Metab 2011, 14:264-271.
48. Zhu S., Li W., Zhou H., Wei W., Ambasudhan R., Lin T., et al. Reprogramming of human primary somatic cells by OCT4 and chemical compounds. Cell Stem Cell 2010, 7:651-655.
49. Davis P.J., Leonard J.L., Davis F.B. Mechanisms of nongenomic actions of thyroid hormone. Front Neuroendocrinol 2008, 29:211-218.
50. Cao X., Kambe F., Yamauchi M., Seo H. Thyroid-hormone-dependent activation of the phosphoinositide 3-kinase/Akt cascade requires Src and enhances neuronal survival. Biochem J 2009, 424:201-209.
51. Izaguirre M.F., Casco V.H. T3 regulates E-cadherin, and beta- and alpha-catenin expression in the stomach during the metamorphosis of the toad Rhinella arenarum. Biotech Histochem 2010, 85:305-323.